Organon (OGN) Goodwill & Intangibles (2020 - 2026)
Organon (OGN) posted quarterly Goodwill & Intangibles of $5.3 billion for Q1 2026, up 11.01% year-over-year from $4.7 billion in Q1 2025, and down 0.59% on a QoQ basis from $5.3 billion in Q4 2025.
Organon (OGN) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Goodwill & Intangibles for 7 consecutive years, with $5.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 11.01% year-over-year to $5.3 billion; the TTM figure through Mar 2026 stood at $5.3 billion (up 11.01% YoY), while the FY2025 annual figure was $5.3 billion, down 13.31% from the prior year.
- Goodwill & Intangibles came in at $5.3 billion for Q1 2026 at Organon, down from $5.3 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $29.1 billion in Q4 2023, with the low at $4.7 billion in Q3 2025.
- Average Goodwill & Intangibles over 5 years is $6.6 billion, with a median of $5.3 billion recorded in 2022.
- Across the five-year window, Goodwill & Intangibles soared 454.53% in 2023 and sank 79.08% in 2024, its largest moves.
- Year by year, Goodwill & Intangibles stood at $5.3 billion in 2022, then jumped by 454.53% to $29.1 billion in 2023, then tumbled by 79.08% to $6.1 billion in 2024, then decreased by 13.31% to $5.3 billion in 2025, then dropped by 0.59% to $5.3 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $5.3 billion, $5.3 billion, and $4.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Bn |
| Dec 31, 2025 | 5.28 Bn |
| Sep 30, 2025 | 4.71 Bn |
| Jun 30, 2025 | 6.04 Bn |
| Mar 31, 2025 | 4.73 Bn |
| Dec 31, 2024 | 6.09 Bn |
| Sep 30, 2024 | 4.72 Bn |
| Jun 30, 2024 | 5.29 Bn |
| Mar 31, 2024 | 4.82 Bn |
| Dec 31, 2023 | 29.12 Bn |
| Sep 30, 2023 | 5.16 Bn |
| Jun 30, 2023 | 5.20 Bn |
| Mar 31, 2023 | 5.22 Bn |
| Dec 31, 2022 | 5.25 Bn |
| Sep 30, 2022 | 5.27 Bn |
| Jun 30, 2022 | 5.24 Bn |
| Mar 31, 2022 | 5.27 Bn |
| Dec 31, 2021 | 5.25 Bn |
| Sep 30, 2021 | 5.29 Bn |
| Jun 30, 2021 | 5.31 Bn |